Nivolumab Induced Lethal Aplastic Anemia in a Patient with Metastatic Melanoma
Nivolumab is an active treatment in patients with metastatic melanoma. We report a case of a patient with metastatic malignant melanoma who was given nivolumab as an advanced-line treatment. She received nivolumab 3 mg/kg every 2 weeks for 4 cycles and developed aplastic anemia. To the best of our k...
Main Authors: | Keren Rouvinov, Karen Nalbandyan, Victor Kozlov, Nir Peled, Alexander Yakobson |
---|---|
Format: | Article |
Language: | English |
Published: |
Karger Publishers
2019-01-01
|
Series: | Case Reports in Oncology |
Subjects: | |
Online Access: | https://www.karger.com/Article/FullText/495980 |
Similar Items
-
Autoimmune hemolytic anemia during long‐term administration of nivolumab for metastatic melanoma
by: Koji Nakajima, et al.
Published: (2021-10-01) -
APLASTIC ANEMIA
by: Ni Made Dharma Laksmi, et al.
Published: (2013-07-01) -
Aplastic Anemia induced by Nivolumab before a Treatment of Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia
by: Wenhan Cheng, et al.
Published: (2019-08-01) -
First-line treatment of metastatic melanoma: role of nivolumab
by: Force J, et al.
Published: (2017-02-01) -
Aplastic anemia in pregnancy
by: Vijay Zutshi, et al.
Published: (2022-01-01)